- Home
- ANGO vs ATAI Comparison
ANGO vs ATAI Comparison
Compare ANGO & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANGO
- ATAI
- Stock Information
- Founded
- ANGO 1988
- ATAI 2018
- Country
- ANGO United States
- ATAI Germany
- Employees
- ANGO N/A
- ATAI N/A
- Industry
- ANGO Medical/Dental Instruments
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- ANGO Health Care
- ATAI Health Care
- Exchange
- ANGO Nasdaq
- ATAI Nasdaq
- Market Cap
- ANGO 400.8M
- ATAI 444.7M
- IPO Year
- ANGO 2004
- ATAI 2021
- Fundamental
- Price
- ANGO $9.33
- ATAI $2.61
- Analyst Decision
- ANGO Strong Buy
- ATAI Strong Buy
- Analyst Count
- ANGO 2
- ATAI 2
- Target Price
- ANGO $15.50
- ATAI $11.00
- AVG Volume (30 Days)
- ANGO 570.7K
- ATAI 5.9M
- Earning Date
- ANGO 07-15-2025
- ATAI 08-12-2025
- Dividend Yield
- ANGO N/A
- ATAI N/A
- EPS Growth
- ANGO N/A
- ATAI N/A
- EPS
- ANGO N/A
- ATAI N/A
- Revenue
- ANGO $283,320,000.00
- ATAI $1,863,000.00
- Revenue This Year
- ANGO N/A
- ATAI $554.22
- Revenue Next Year
- ANGO $6.35
- ATAI N/A
- P/E Ratio
- ANGO N/A
- ATAI N/A
- Revenue Growth
- ANGO N/A
- ATAI 572.56
- 52 Week Low
- ANGO $5.67
- ATAI $1.03
- 52 Week High
- ANGO $13.50
- ATAI $2.99
- Technical
- Relative Strength Index (RSI)
- ANGO 43.45
- ATAI 58.55
- Support Level
- ANGO $9.12
- ATAI $2.62
- Resistance Level
- ANGO $9.78
- ATAI $2.99
- Average True Range (ATR)
- ANGO 0.40
- ATAI 0.23
- MACD
- ANGO -0.09
- ATAI 0.02
- Stochastic Oscillator
- ANGO 26.24
- ATAI 58.89
About ANGO AngioDynamics Inc.
AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.